Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 10/20 | 0.65 |
| ▸ | SLC6A4 | P31645 | 10/20 | 0.65 |
| ▸ | SLC6A3 | Q01959 | 10/20 | 0.65 |
| ▸ | MITF | O75030 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | CA4 | P22748 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10413244 | 1.00 | SLC6A2 (0.65) | SLC6A2SLC6A4SLC6A3MITFCA1 | |
| SCHEMBL22285003 | 1.00 | SLC6A2 (0.65) | SLC6A2SLC6A4SLC6A3MITFCA1 | |
| SCHEMBL21599192 | 0.85 | GBA1 (0.54) | SLC6A2SLC6A4SLC6A3MITF | |
| SCHEMBL15062243 | 0.84 | SLC18A2 (0.51) | SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL4934485 | 0.84 | SLC6A2 (0.47) | SLC6A2SLC6A4SLC6A3MITFCA1 | |
| SCHEMBL28475644 | 0.84 | SLC6A2 (0.47) | SLC6A2SLC6A4SLC6A3MITF | |
| SCHEMBL4149173 | 0.82 | CA1 (0.47) | SLC6A2SLC6A4SLC6A3MITFCA1 | |
| SCHEMBL13323425 | 0.82 | SLC6A4 (0.52) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL20247261 | 0.81 | SIGMAR1 (0.53) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL12520753 | 0.81 | SLC6A2 (0.44) | SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9914730-B2 | Azaquinazoline inhibitors of Atypical protein Kinase C | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-03-13 | — | — | US | disclosed |
| US-9896446-B2 | Azaquinazoline inhibitors of atypical protein kinase C | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-02-20 | — | — | US | disclosed |
| US-20160102094-A1 | Azaquinazoline Inhibitors of Atypical Protein Kinase C | IGNYTA, INC. (US) | 2016-04-14 | — | — | US | disclosed |
| US-6518273-B1 | 2-aryl indole derivative as antagonists of tachykinins | MERCK SHARP & DOHME LTD. | 2003-02-11 | — | — | US | disclosed |
| WO-2000051984-A1 | 2-ARYL INDOLE DERIVATIVES AS ANTAGONISTS OF TACHYKININS | MERCK SHARP & DOHME LIMITED (GB) | 2000-09-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160102094-A1 | Azaquinazoline Inhibitors of Atypical Protein Kinase C | PRKCQ, PRKCZ, PRKCE | SLC6A2 4635/4885SLC6A4 4641/4885SLC6A3 4045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.